On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results

  • Biotechnology innovator BiondVax Pharmaceuticals recently provided a business update and published full-year financial results for the period ended December 31, 2022
  • Achievements realized to date leave CEO Amir Reichman optimistic about the company’s growth potential and ability to deliver value to shareholders
  • The company enjoys definitive, exclusive agreements including options for exclusive worldwide licenses with the Max Planck Society and the University Medical Center Göttingen, Germany to enable it to build a pipeline of ‘biobetter’ nanosized VHH antibodies (“NanoAbs”)
  • Pipeline to target diseases with attractive commercial opportunities such as psoriasis, psoriatic arthritis, COVID-19, macular degeneration and asthma

Biotechnology innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) recently provided a business update, published its full-year financial results for the period ended December 31, 2022, and filed its annual report on Form 10-K with the Securities and Exchange Commission (“SEC”) (https://ibn.fm/GsIVG). The business update reflected recent highlights and achievements that company CEO Amir Reichman says leave him “optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders.”

A developmental stage biotech company keen on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, BiondVax in late 2021 and early 2022 entered into definitive agreements with the Max Planck Society (“MPG”)’s Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”) and the University Medical Center Göttingen, Germany (“UMG”) to enable the company build a pipeline of ‘biobetter’ nanosized VHH antibodies (“NanoAbs”).

These alpaca derived NanoAbs not only possess unique physicochemical characteristics – such as target neutralization at lower drug concentrations, convenient routes of administration, formulation advantages, stability at high temperatures, and greater binding affinity – but also exhibit strong potential for a number of significant competitive advantages over currently approved human monoclonal antibodies (“mAbs”) targeting diseases with attractive commercial opportunities.

“The company believes that if NanoAbs with these attributes are developed as drug candidates for specific indications where their attributes present an advantage over currently marketed mAbs, they would provide an opportunity to capture a meaningful share of several large and growing markets,” the business update reads.

Furthermore, the company believes the focus on NanoAbs with targets already validated by mAbs will help reduce the upfront costs and risks commonly associated with new drug development, especially given that the mechanism of action of antibodies on target molecules has already been established. Thus, the initiation of clinical development would be accelerated. Moreover, the company holds, “having access to a multi-asset pipeline would hedge BiondVax’s risk and provide greater opportunity and flexibility in pursuing partnering deals with other pharma companies.”

The BiondVax-MPG-UMG agreements include an exclusive worldwide licensing agreement allowing the company to develop and commercialize anti-SARS-CoV-2 NanoAbs. Subsequently, BiondVax developed innovative inhaled anti-SARS-CoV-2 NanoAbs that were the subject of a successful preclinical in vivo study evaluating their therapeutic and prophylactic capabilities. The study unearthed highly positive results showing showed that the NanoAbs not only virtually eliminated the virus in the lungs (https://ibn.fm/QN24C) and led to a significantly shorter and milder illness (https://ibn.fm/pVcuC) but also prevented illness (https://ibn.fm/NNGOG). Guided by these positive results, the company is currently assessing plans to commence a Phase 1/2a clinical trial.

The company also holds an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized under the agreement. Against this backdrop and based on promising results from a research collaboration agreement (“RCA”) with MPI-NAT and UMG, BiondVax last year announced its intention to next focus development on NanoAbs that target immune system cytokines such as IL-17, IL-13, and TSLP as drug candidates for the potential treatment of psoriasis, psoriatic arthritis, and asthma (https://ibn.fm/kkhgK).

“Looking ahead, I’m excited to exercise our option to obtain an exclusive license at pre-agreed financial terms to anti-IL-17 NanoAbs targeting safe, effective, and convenient treatment of psoriatic lesions; scale up in-house NanoAb manufacturing; and conduct an in vitro proof-of-concept study and potentially also a preclinical trial of the IL-17 NanoAb as a therapy for psoriasis,” CEO Amir Reichman stated.

The company also plans to offer interested parties its cGMP manufacturing capabilities, including experienced professionals for CDMO (Contract Development and Manufacturing Organization) services, laboratories, and aseptic fill and finish suite, with the objective of optimizing the use of its assets and generating revenues. Still, the company will prioritize its NanoAb pipeline development, extending its focus on research and development (“R&D”), which saw the company increase its R&D expenses from $3.2 million in 2021 to $5.7 million in 2022.

“The BiondVax team, in collaboration with our scientific partners from MPI-NAT and UMG, has worked exceedingly hard to develop best-in-class capabilities in NanoAb technology-based drug development,” Reichman added. “I want to thank our shareholders for their continued support as we progress toward building the company into a financial success by providing caregivers and patients with high-quality, innovative, de-risked pharmaceutical products that help protect and improve human life.”

As documented in its financial summary, BiondVax also reported cash and cash equivalents of $14 million and working capital of $6.7 million as of December 31, 2022. According to the Form 10-K filing, the company expects its existing capital resources will enable it to fund its operating expenses and capital expenditure requirements for at least the next 12 months (https://ibn.fm/IBe7B).

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.comw
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered